Company intelligence / Profile preview

TregTherapeutics Inc.

North Carolina, United Statestregtherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

TregTherapeutics is developing a universal tolerance induction therapy for autoimmune disease using its proprietary TILAC™ platform. The company’s lead program, TREG101, is being prepared for human proof-of-concept studies. The approach aims to demonstrate safety and efficacy in humans before seeking partnerships with larger biopharma companies to advance through later clinical stages and commercialization[1].

Therapeutic areas: Immunology
Modalities: Immune tolerance induction platform (TILAC™)Linked adjuvant/cytokine conjugate therapy
Industry: Biotech

Drug pipeline

7 assets

TREG101

Preclinical

6 more assets in the full pipeline.

Request access →

Partnerships

Exclusive license from East Carolina University[1]

Beyond the preview

Go deeper on TregTherapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TregTherapeutics Inc..

Explore the full profile